Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Lung Cancer
Advertisement
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Mara Antonoff, MD, explains the nuances of determining if a patient with oligometastatic disease is a candidate for surgery.
A study of nearly 10,000 lung cancer cases found that only 41% would have been eligible for screening per USPSTF guidelines.
The study is evaluating if hydrogen peroxide in exhaled breath condensate can be used as a biomarker for lung cancer.
Ravi Rajaram, MD, MSc, discusses Medicaid expansion, timely access to care, regionalization effects, and remaining questions.
Michael R. Gieske, MD, discusses why Lung Cancer Action Week is a key time to promote screening and shares recent milestones.
Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
The ALA and its LUNG FORCE initiative are lighting up buildings and landmarks across the nation this week to inspire action.
Mara Antonoff, MD, discusses key advances and addresses common misconceptions about operating in oligometastatic disease.
The new report from the National Cancer Institute also showed rates of new lung and bronchus cancers fell the most rapidly.
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.